Medicenna Therapeutics reports developments as a clinical-stage immunotherapy company developing proprietary Superkines for cancer, autoimmune and inflammatory diseases. Recurring updates center on MDNA11, a long-acting IL-2 Superkine; MDNA113, a tumor-targeted and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine; and bizaxofusp, formerly MDNA55, an IL-4 Empowered Superkine studied in glioblastoma.
Company news also includes clinical and preclinical data presentations at oncology and healthcare conferences, corporate and financial updates, collaborations around investigator-initiated trials, and governance changes such as board and medical leadership appointments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.